Mark William Lowdell - 02 Jul 2026 Form 4 Insider Report for Inmune Bio, Inc. (INMB)

Reporting relationship: Chief Scientific Officer
Issuer ticker: INMB
Reported as of: 02 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jul 2026, 07:01:16 UTC
Prior SEC filing: 02 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark William Lowdell

Key filing fact

Mark William Lowdell filed Form 4 for Inmune Bio, Inc. (INMB) on 07 Jul 2026.

Key facts

This page summarizes Mark William Lowdell's Form 4 filing for Inmune Bio, Inc. (INMB).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Jul 2026, 07:01.

Change

Previous filing in this sequence was filed on 02 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001767037 Primary reporting owner

Lowdell Mark William

Relationship: Chief Scientific Officer
Address: C/O INMUNE BIO INC., 225 NE MIZNER BLVD., SUITE 640, BOCA RATON
Signature: /s/ Mark William Lowdell
Signature date: 07 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INMB transaction

Common Stock

Options Exercise

Transaction value
Shares: +7,211
Change %: +0.48%
Price: $1.40^*
Shares after: 1,518,017
Date: 02 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INMB transaction Derivative

Common Stock Purchase Warrant

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: -7,211
Change %: -50%
Price: $0.1250^*
Shares after: 7,212
Date: 02 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,211
Exercise price: $1.40

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents 7,211 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 7,211 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 7,211 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027.